Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2014-11-28 17:11:53 |
Versijas komentārs | |
Teksts |
Olaine, 2014.gada 28.novembrī
Profit of
„Olainfarm” Has Increased by 37% in Nine Months
Unaudited profit and
loss account for 9 months of 2014 shows that the group has
experiences its best nine months so far as it made the net profit
of 12.1 million euros and sales of 69.9 million euros. Net
profit has increased by
37%, whereas new sales by 30% compared to the same period one year
ago. The major sales markets of AS “Olainfarm”
during this period were Russia, Latvia, Ukraine, Belarus and The
Netherlands.
Also a third quarter has been the most successful third quarter
for AS „Olainfarm” in terms of sales so far, as it made sales
of 21.3 million euros, which represents an increase by 12% compared
to the same period of last year. Net profit of the company
during this quarter was 3.2 million euro. This represents a
reduction by 12.5% compared to the last year, but it has to be
noted that due to economic difficulties in two of company’s key
markets, the company decided to create provisions of 0.7 million
euros for Russian and Ukrainian receivables..
„We have experienced the best third quarter in terms of sales and
the best nine months in terms of the net profit in our
history. This and the next year our main focus will be on
significant improvement of company’s infrastructure as well as
increase of our presence in new export markets. We are glad
to have new market authorisations in countries that are hardly
typical for us, including Peru,
Bhutan, Mongolia, Romania and Kosovo. First shipment to
Mongolia might even take place later this year,” says Valerijs
Maligins, Chairman of the Board of AS „Olainfarm”.
During nine months of 2014 sales to all company’s main markets
continued increasing except for Kazakhstan, where they shrunk by
11%, compared to the same period of 2013. To a large extent
such reduction was caused by the devaluation of Kazakhstan’s
currency, but the decline in sales slowed down during the third
quarter. The most rapid sales increases during the reporting period
were achieved to Poland, where sales grew by 714%, The Netherlands
by 184%, Ukraine by 119%, and Lithuania by 94. In total
during nine months products of AS „Olainfarm” were sold to 32
countries in 5 continents.
During the 9 months of 2014 35 registration cases have been
approved in several countries, including such untraditional
countries for AS “Olainfarm” as Peru, Mongolia, Bhutan, Romania and
Kosovo. Several products are still in the process of
obtaining MAs, among other countries, in Turkey, registration
processes have been launched in Bosnia and Herzegovina and other
new markets. Preclinical trials of R-phenylpiracetam are
being conducted and totally new forms and line extensions of
existing products are being developed. Among other things the
company works at development of a new nootropic medication, new
product of nitrofurantoine group and a new food supplement.
New final dosage laboratory is undergoing a significant
modernisation.
Annual meeting of shareholders of A/s “Olainfarm” held on April 29,
2014 approved operating plan of the Group. According to it,
sales of the Group in 2014 are planned to be 93 million euros, but
the net profit will reach 15 million euros. According to this
unaudited report for 9 months of 2014, during this period 75.2% of
annual sales target and 80.7% of annual profit target is
met.
JSC
Olainfarm is one of the biggest pharmaceutical companies in Latvia
with more than 40 years of experience in production of medication
and chemical and pharmaceutical products. A basic principle of
company's operations is to produce reliable and effective top
quality products for Latvia and the rest of the world. Products
made by the Group are being exported to more than 35 countries of
the world, including the Baltics, Russia, other CIS, Europe, Asia,
North America and Australia
Information
prepared by:
|
Pielikumi |